Having a previous SARS-CoV-2 infection provided a gradient of protection against reinfection, especially against severe forms of COVID-19.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – As traditional research institutions ...

Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for ...

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New ...

Clear signs of immune activation: ICT01 at the 10 mg dose provided optimal activation of γ9δ2 T cells and a downstream immune ...

What happens when the dengue virus enters the body? What kind of immunity cells does it encounter? What does the body's ...

Paraneoplastic syndromes affect multiple organs and are a central cause of mortality in cancer patients. In this issue, Cong et al ( 2025) report an inflammatory gut-kidney axis mediating systemic ...

As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated ...

Fintel reports that on May 20, 2025, Lake Street initiated coverage of Bolt Biotherapeutics (NasdaqCM:BOLT) with a Buy recommendation. Analyst Price Forecast Suggests 291.64% Upside As of May 7, 2025, ...

Detailed price information for Cero Therapeutics Holdings Inc (CERO-Q) from The Globe and Mail including charting and trades.

GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion ...